anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed are hydrogels polymerized with a free radical scavenger, for example a spin trap. The hydrogels are biodegradable and permanent, designed to be implantable in a mammalian body and intended to block or mitigate the formation of tissue adhesions. The hydrogels of the present invention are characterized by comprising four structural elements: (a) a polymeric backbone which defines the overall polymeric morphology, (b) linkage groups, (c) side chains, and (d) spin trap end groups. The hydrophobicity of the various structural elements are chosen to reduce tissue adhesion and enhance the free radical scavenging aspect of the end groups. The morphology of these polymers are typically of high molecular weight and have shape to encourage entanglement. Useful structures include branching chains, comb or brush, and dendritic morphologies.
NEW MATERIAL:Anti-OMC-4 monoclonal antibody having a specificity against a cultured cell strain, OMC-4, originated from human uterine cervix cancer. USE:A diagnostic agent for diagnosing the cells or tissue of the cancer or a treating agent of the cancer. PREPARATION:For example, a cultured cell strain OMC-4 originated from human uterine cervix cancer prepared by culturing a tumor tissue extracted from the diseased portion of a uterine cervix cancer patient is dosed to a BALB/c mouse to immunize the mouse. After the final immunization, the spleen is extracted and splenic cells are taken out. The splenic cells are fused with myeloma cells originated from a BALB/c mouse and cultured in a HAT medium to prepare hybridomas. A clone producing the anti-OMC-4 antibody is screened from the hybridomas, cloned by a limiting dilution method and subsequently cultured to provide the anti-OMC-4 monoclonal antibody.
PURPOSE:To obtain the title pharmaceutical capable of stopping drug release for a specified time after its initial release due to application and then of releasing the drug again, by providing a flexible substrate with a drug-contg. polymer layer and thereon by laminating a drug-impermeable but water-permeable polymer layer and a pressure-sensitive adhesive layer. CONSTITUTION:A flexible, drug-impermeable substrate 2 (e.g. polyolefin film) is provided with a drug-contg. polymer layer 3 (e.g. silicone rubber) and then laminated with a virtually drug-impermeable but water-permeable polymer layer 4 (e.g. cellulose) and a pressure-sensitive adhesive layer 5 (e.g. vinyl viscous material) in this order, thus obtaining the objective pharmaceutical. The pressure-sensitive adhesive layer, according to therapeutic purposes, may be incorporated with the drug. The present pharmaceutical is useful for preventing the development of drug tolerance. Furthermore, because one application enables repeated drug release twice or more, the trouble of reapplication can be saved. Also, two or more kinds of drug can be put to percutaneous absorption with staggered time.
Included 15 patients who are participating in an aerobic interval training exercise program only. The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks.
A device or composition that is at least in part degradable, the composition comprises at least two inorganic components at least one of the components is degradable. In an embodiment a glass structure with a shell made of glass A and a core made of glass B, where glass A degrades slower that glass B is described. Glass A can be a slowly degrading phosphate glass or a silicate glass formulation of the 45S5 Bioglass type. Glass B can be a phosphate- or silicate-based glass. In an embodiment the devices or compositions is of either fibre or particulate form. The compositions and devices may be used in medical devices such as orthopaedic reconstruction and trauma products, for instance implants, pins or plates.
Buprenorphine hydrochloride sublingual tablets are white, round, unscored tablets, debossed with M over 923 (2 mg) or M over 924 (8 mg) on one side of the tablet and blank on the other side. They contain buprenorphine hydrochloride, a partial agonist at the mu-opioid receptor, and are available in two dosage strengths, 2 mg buprenorphine and 8 mg buprenorphine (as the free base, equivalent to 2.156 mg buprenorphine hydrochloride, USP and 8.624 mg buprenorphine hydrochloride, USP). Each tablet also contains anhydrous citric acid, anhydrous lactose, colloidal silicon dioxide, corn starch, crospovidone, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose and sodium citrate. 

Chemically, buprenorphine hydrochloride is 21-Cyclopropyl-7α-[( S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14- endo-ethano-6,7,8,14-tetrahydrooripavine hydrochloride. It has the following chemical structure: 

Buprenorphine hydrochloride, USP has the molecular formula C 29H 41NO 4•HCl and the molecular weight is 504.10. It is a white or off-white powder, sparingly soluble in water, freely soluble in methanol, soluble in alcohol and practically insoluble in cyclohexane.
BACKGROUND: Studies have shown inconclusive results on the effectiveness of cerebral protection devices (CPDs) with transcatheter aortic valve replacement. We aimed to analyze the national statistics on stroke and other outcomes with CPD use.
METHODS AND RESULTS: The Nationwide Readmissions Database (2017-2020) was queried to obtain data on patients undergoing transcatheter aortic valve replacement. Outcomes were compared between patients with a CPD and patients without a CPD. Of 271 804 patients undergoing transcatheter aortic valve replacement, CPD was used in 7.3% of patients. In a multivariable logistic regression analysis, CPD use was not associated with lower overall stroke rates (1.6% versus 1.9% without CPD; odds ratio, 0.95 [95% CI, 0.84-1.07]; P=0.364), but it was significantly associated with lower major stroke rates (1.2% versus 1.5% without CPD; odds ratio, 0.85 [95% CI, 0.74-0.98]; P=0.02). Patients with a CPD also had a shorter length of stay, higher routine discharges to home/self-care (74.9% versus 70.6%), and lower mortality rates (0.7% versus 1.3%). The 30-day (9.6% versus 11.7%) and 180-day (24.6% versus 28.2%) readmission rates were significantly lower in the CPD cohort. Among patients who developed stroke, patients with a CPD had more frequent routine discharges. Prior valve surgery was associated with the highest risk of overall and major stroke.
CONCLUSIONS: CPD use during transcatheter aortic valve replacement was not independently associated with a lower risk of overall stroke but was associated with a lower risk of major stroke in a multivariable model. Data from future randomized trials that may offset any potential confounders in our study are required to help identify patients who would benefit from the use of these devices.
Nedocromil sodium is a mast cell stabilizer. Nedocromil sodium inhibits the release of mediators from cells involved in hypersensitivity reactions. Decreased chemotaxis and decreased activation of eosinophils have also been demonstrated.

In vitro studies with adult human bronchoalveolar cells showed that nedocromil sodium inhibits histamine release from a population of mast cells having been defined as belonging to the mucosal sub type and inhibits beta-glucuronidase release from macrophages.

Pharmacokinetics and Bioavailability

Nedocromil sodium exhibits low systemic absorption. When administered as a 2% ophthalmic solution in adult human volunteers, less than 4% of the total dose was systemically absorbed following multiple dosing. Absorption is mainly through the nasolacrimal duct rather than through the conjunctiva. It is not metabolized and is eliminated primarily unchanged in urine (70%) and feces (30%).
Topiramate, USP is a sulfamate-substituted monosaccharide. Topiramate capsules, USP are available as 15 mg and 25 mg sprinkle capsules for oral administration as whole capsules or opened and sprinkled onto soft food.

Topiramate, USP is a white to off-white powder. Topiramate, USP is freely soluble in dichloromethane. Topiramate, USP has the molecular formula C12H21NO8S and a molecular weight of 339.36. Topiramate, USP is designated chemically as 2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamate and has the following structural formula:

Topiramate capsules, USP intended for oral administration contains 15 mg or 25 mg of topiramate, USP. The inactive ingredients are cellulose acetate, gelatin, povidone, sodium lauryl sulfate, sugar spheres, talc and titanium dioxide. The imprinting ink has the following components: black iron oxide, potassium hydroxide, propylene glycol, shellac.

FDA approved dissolution test specifications differ from USP.
This is a randomized, double-blind, sham-controlled study using transcranial Direct Current Stimulation (tDCS) for 4-week treatment. After the intervention of tDCS, there is a follow up visit at week 8 in order to understand the long-term effects of tDCS. Participants were randomly assigned 1:1 to tDCS group or sham-control group. Active tDCS comprised 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks. Sham was administered similarly, but with current turned off after 30s. Apart from studying the effects of tDCS on severity of depression and cognitive function, the secondary outcomes are to examine biomarkers related to inflammatory activity. Scale assessments are performed before the initiation of treatment, week 1, week 2, week 3, week 4 and week8. Collection of blood, excrement and saliva takes place at three time points, at the baseline, week 4 and week 8.
Stoppa approach was more minimally invasive than ilioinguinal approach for pelvic and acetabular fractures. Then, Stoppa approach was widely used clinically. For the fragments involving quadrilateral surface, the Kocher-Langenbeck approach was added because the fixation of posterior fragments could not be obtained with reconstruction plate through single Stoppa approach. Novel quadrilateral surface plate was used in this study to examine its fixed role for posterior fragments. Functional outcome and complication were recorded to compare with the results treated with reconstruction plate. If good results were obtained for the patients fixed with quadrilateral surface plate, it was meaningful to popularize the fixed method.
Cefazolin for Injection may be used in patients with reduced renal function with the following dosage adjustments: Patients with a creatinine clearance of 55 mL/min or greater or a serum creatinine of 1.5 mg % or less can be given full doses. Patients with creatinine clearance rates of 35 to 54 mL/min or serum creatinine of 1.6 to 3 mg % can also be given full doses but dosage should be restricted to at least 8 hour intervals. Patients with creatinine clearance rates of 11 to 34 mL/min or serum creatinine of 3.1 to 4.5 mg % should be given 1/2 the usual dose every 12 hours. Patients with creatinine clearance rates of 10 mL/min or less or serum creatinine of 4.6 mg % or greater should be given 1/2 the usual dose every 18 to 24 hours. All reduced dosage recommendations apply after an initial loading dose appropriate to the severity of the infection. Patients undergoing peritoneal dialysis: See CLINICAL PHARMACOLOGY.
The invention relates to a smoking therapy used for treating senile cataract. With the increase of age, cataract occurs to more and more elderly friends. Senile cataract is mainly because of age, environment pollution or prolonged bright light stimulation. If cataract is not treatment in time, cataract may evolve into vision loss in late-stage. Cataract brings a great threat to people's health. According to current treatment methods, surgery is mainly adopted. The cost is expensive, and the risk is great. The elderly cannot recovery well after surgery. The smoking therapy designed by using traditional Chinese medicine can provide a good therapeutic effect upon patients of senile cataract. The therapy has a lower cost compared to surgery, and has a better effect. The therapy causes no side effect, and patients can recover easily.
INTRODUCTION: Non-communicable diseases (NCDs) are rising in low-income and middle-income countries, including Malawi. To inform policy-makers and planners on the preparedness of the Malawian healthcare system to respond to NCDs, we estimated NCD service readiness in publicly financed healthcare facilities in Malawi.
METHODS: We analysed data from 564 facilities surveyed in the 2019 Harmonised Health Facility Assessment, including 512 primary healthcare (PHC) and 52 secondary and tertiary care (STC) facilities. To characterise service readiness, applying the law of minimum, we estimated the percentage of facilities with functional equipment and unexpired medicines required to provide NCD services. Further, we estimated permanently unavailable items to identify service readiness bottlenecks.
RESULTS: Fewer than 40% of PHC facilities were ready to deliver services for each of the 14 NCDs analysed. Insulin and beclomethasone inhalers had the lowest stock levels at PHC facilities (6% and 8%, respectively). Only 17% of rural and community hospitals (RCHs) have liver and kidney diagnostics. STC facilities had varying service readiness, ranging from 27% for managing acute diabetes complications to 94% for chronic type 2 diabetes management. Only 38% of STC facilities were ready to manage chronic heart failure. Oral pain medicines were widely available at all levels of health facilities; however, only 22% of RCHs and 29% of STCs had injectable morphine or pethidine. Beclomethasone was never available at 74% of PHC and 29% of STC facilities.
CONCLUSION: Publicly financed facilities in Malawi are generally unprepared to provide NCD services, especially at the PHC level. Targeted investments in PHC can substantially improve service readiness for chronic NCD conditions in local communities and enable STC to respond to acute NCD complications and more complex NCD cases.
BACKGROUND Care bundles for infection control consist of a set of evidence-based measures to prevent infections. This retrospective study aimed to compare surgical site infections (SSIs) from a single hospital surveillance system between 2017 and 2020, before and after implementing a standardized care bundle across specialties in 2019. It also aimed to assess whether bundle compliance affects the rate of SSIs. MATERIAL AND METHODS A care bundle consisting of 4 components (peri-operative antibiotics use, peri-operative glycemic control, pre-operative skin preparation, and maintaining intra-operative body temperature) was launched in 2019. We compared the incidence rates of SSIs, standardized infection ratio (SIR), and clinical outcomes of surgical procedures enrolled in the surveillance system before and after introducing the bundle care. The level of bundle compliance, defined as the number of fully implemented bundle components, was evaluated. RESULTS We included 6059 procedures, with 2010 in the pre-bundle group and 4049 in the post-bundle group. Incidence rates of SSIs (1.7% vs 1.0%, P=0.013) and SIR (0.8 vs 1.48, P<0.01) were significantly lower in the post-bundle group. The incidence of SSIs was significantly lower when all bundle components were fully adhered to, compared with when only half of the components were adhered to (0.3% vs 4.0%, P<0.01). CONCLUSIONS SSIs decreased significantly after the application of a standardized care bundle for surgical procedures across specialties. Full adherence to all bundle components was the key to effectively reducing the risk of surgical site infections.
Dose escalation of SYN125 administered with a fixed-dose of SYN004 (SYN004 will be administered immediately after SYN125 infusion is complete, if tolerated). Once cohorts with low and medium dose levels in Part A are completed and no DLTs are observed per cohort, Part B with the SYN125 low dose level + SYN004 will start and run in parallel with Part A. The high dose of SYN125 in a cohort in Part A will begin along with Part B.
PURPOSE: Extracting inclusion and exclusion criteria in a structured, automated fashion remains a challenge to developing better search functionalities or automating systematic reviews of randomized controlled trials in oncology. The question "Did this trial enroll patients with localized disease, metastatic disease, or both?" could be used to narrow down the number of potentially relevant trials when conducting a search.
METHODS: Six hundred trials from high-impact medical journals were classified depending on whether they allowed for the inclusion of patients with localized and/or metastatic disease. Five hundred trials were used to develop and validate three different models, with 100 trials being stored away for testing. The test set was also used to evaluate the performance of GPT-4o in the same task.
RESULTS: In the test set, a rule-based system using regular expressions achieved F1 scores of 0.72 for the prediction of whether the trial allowed for the inclusion of patients with localized disease and 0.77 for metastatic disease. A transformer-based machine learning (ML) model achieved F1 scores of 0.97 and 0.88, respectively. A combined approach where the rule-based system was allowed to over-rule the ML model achieved F1 scores of 0.97 and 0.89, respectively. GPT-4o achieved F1 scores of 0.87 and 0.92, respectively.
CONCLUSION: Automatic classification of cancer trials with regard to the inclusion of patients with localized and/or metastatic disease is feasible. Turning the extraction of trial criteria into classification problems could, in selected cases, improve text-mining approaches in evidence-based medicine. Increasingly large language models can reduce or eliminate the need for previous training on the task at the expense of increased computational power and, in turn, cost.
The invention relates to medicine, in particular to soft medicinal agents for external application (ointment, gels, emulsions, liniments) and can be used for treating thermal, solar and chemical burns of human beings and animals. The inventive pharmaceutical composition for treating burns is embodied in the form of a gel and contains an active substance N-(β-oxyethyl)-4,6-dimethyldihydropyrimidone-2 (xymedon), a gel former, a moisture retaining agent and distilled water. The gel former can be embodied in the form of sodium, carboxymethylcellulose, sodium alginates or the mixture thereof and the moisture retaining agent is embodied in theform of glycerin. In the other embodiments, additionally to xymedon, the composition can contain an active substance in the form of silver nitrate or silver nitrate and sodium sulphacyl or levomycetin and amber acid. The test have proved the high efficiency of said composition, which meets all the medical and biological requirements of modern medicinal agents used for treating burns and wounds. The pharmaceutical composition is embodied in the form of a gel and can be used as highly efficient regenerating, wound-healing and micro-circulation improving means for treating infected burn wound.
The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Ying Tang were used.
Norepinephrine Bitartrate in Sodium Chloride Injection is filled in 250 mL transparent intravenous Nexcel bags as:

Each filled bag is packed in an overwrap with a transparent band and oxygen absorber and oxygen indicator placed inside the overwrapping to prevent deterioration of drug product. Product should be used within 7 days of removal from overwrap.

Do not use the product if the oxygen indicator has changed color to green or blue before opening the overwrap. Normal color is yellow or orange.

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature] in the original carton to protect from light. Do not freeze.
Classical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area \<1 cm2, mean gradient \<40 mmHg, ejection fraction \<50% and stroke volume index (SVi) ≤35 mL/m2 by resting transthoracic echocardiography. Dobutamine stress echocardiography is not mandatory for the definition of classical LFLG AS. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
The sample was selected and recruited from patients attending two centres (Orthodontic Department at Karbala Governmental Specialized Dental Center and Almina Dental Private Clinics/Karbala), but the bonding and follow up sessions were done in Almina Dental Private Clinics/Karbala. Patient recruitment was done according to specified inclusion and exclusion criteria.

Intervention procedure planned to be by bonding fixed orthodontic appliances to all patients. The four quadrants of the mouth will be divided into two groups (Group 1 and 2), with one group, the upper right and lower left quadrants bonded with nCaF2 resin, while the upper left and lower right quadrants bonded with control resin. For the other group, the reverse will be carried out. Then, by the use of a computer random number generator, the two groups will be randomly allocated, and each number in the random table will be given a study number in order to create the final Allocation Table for the participants in the study (which contained the study number and allocation group). the primary planned to be measured by DIAGNOdent Pen 2190 device to measure enamel demineralization objectively, while the secondary objective planned to be quantitative detection of Streptococcus mutans bacteria by using real-time PCR
Interleukin (IL)-17A and then IL-17F have been discovered through their roles in chronic inflammatory diseases. These cytokines share 50% of sequence homology and bind to the same receptor made of the IL-17RA et IL-17RC chains. While they have rather similar pro-inflammatory effects, slight differences exist depending on the cell type considered or whether there is TNF or not. Indeed, there is a synergistic effect of TNF and IL-17A or IL-17F on many cell types. In addition, the interactions between immune and stromal cells also modulate their effects which vary according to stromal cell subtype. The identification of IL-17A and IL-17F roles in inflammatory diseases, as psoriasis, has led to the development of inhibitors of those cytokines. Anti-IL-17A, then anti-IL-17A/F and now anti-IL-17RA have been approved for different diseases and are particularly efficient in psoriasis. Their use is expending to other diseases like psoriatic arthritis and spondyloarthritis. Last, the recent understanding of the importance of stromal cells during chronic inflammation explains the relative inefficacy of such inhibitors in some other diseases.
The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.